898 Transcriptional expression analysis in oncogene-addicted lung cancers identifies immune regulators under commercial development that could be therapeutic targets for ALK-positive lung cancer

20250 citationsJournal Articlehybrid Open Access

Authors

Ken Culver · Positive Impact

Sadia Yaakov · Positive Impact

Emily S. Venanzi · Positive Impact

Zhengyu Ouyang · Associates in Neurology

Kejie Li · Associates in Neurology

Marc A. T. Muskavitch · Positive Impact

Abstract

Table 1 Potential therapeutic immune regulator targets, expressed in 100% of ALK+, EGFR+ and KRAS+ oncogene-addicted lung cancers, for which drugs are in development

Topics & Keywords

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies

Publication Details

Published in: Regular and Young Investigator Award Abstracts

DOI: 10.1136/jitc-2025-sitc2025.0898

Field-Weighted Citation Impact: 0.00

Command Palette

898 Transcriptional expression analysis in oncogene-addicted lung cancers identifies immune regulators under commercial development that could be therapeutic targets for ALK-positive lung cancer

Authors

Abstract

Topics & Keywords

Publication Details